pamrevlumab
Another Phase 3 flop for FibroGen as DMD drug fails to improve mobility
Anika Sharma
FibroGenās troubles continue to mount. The biotech announced its fourth phase 3 failure in four months after the market closed ...
most recent
Latest News, Deals, Pharma
Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer
Pharma, Clinical Trials, Latest News
Vertex Halts Phase 2 Lung Therapy, Reevaluates DMD Drug’s Clinical Path
Latest News, Clinical Trials, Pharma
Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%
Latest News, Pharma
J&J MedTech Plans US Clinical Trials for Ottava Surgical Robot in Late 2024
